Tredegar Corporation filed its quarterly report on Form 10-Q with the SEC on August 7, 2026, covering the three and six months ended June 30, 2026, disclosing higher sales, improved net income from continuing operations, and an expanded balance sheet compared to the prior-year period.

Key Highlights

  • Q2 2026 sales of $216,236 thousand, up from $179,116 thousand in Q2 2025, according to the filing.
  • Net income from continuing operations was $6,047 thousand for Q2 2026, compared with $1,828 thousand in Q2 2025.
  • Six-month net income totaled $11,678 thousand for the first half of 2026, versus $11,832 thousand for the same period in 2025.
  • Total assets stood at $412,925 thousand as of June 30, 2026, up from $371,372 thousand at December 31, 2025.
  • Cash and cash equivalents increased to $17,179 thousand at June 30, 2026, from $6,729 thousand at December 31, 2025.
  • Shares outstanding were 34,925,717 at June 30, 2026, with 34,944,164 shares outstanding as of July 31, 2026.
  • ABL revolving facility balance was $46,000 thousand at June 30, 2026, compared with $34,550 thousand at December 31, 2025.

Tredegar's Second-Quarter 2026 Financial Performance and Balance Sheet Position

Tredegar Corporation (New York Stock Exchange: TG), a Virginia-based manufacturer headquartered at 1100 Boulders Parkway, Richmond, reported second-quarter 2026 sales of $216,236 thousand, an increase from $179,116 thousand in the second quarter of 2025, according to the filing. Cost of goods sold rose to $180,784 thousand from $148,535 thousand in the prior-year quarter. Income from continuing operations before income taxes was $7,778 thousand for Q2 2026, compared with $2,812 thousand for Q2 2025. After income tax expense of $1,731 thousand, net income from continuing operations reached $6,047 thousand. Diluted earnings per share from continuing operations were $0.17 for Q2 2026, versus $0.05 in Q2 2025.

For the six months ended June 30, 2026, the company reported sales of $402,725 thousand, up from $343,853 thousand for the same period in 2025. Six-month net income from continuing operations was $11,117 thousand, compared with $2,500 thousand in the prior-year period. Income from discontinued operations, net of tax, contributed $561 thousand in the first half of 2026, versus $9,332 thousand in the first half of 2025, reflecting proceeds and activity related to the sale of Terphane, as disclosed in the cash flow statement. Six-month diluted earnings per share were $0.34 in both 2026 and 2025.

On the balance sheet, total current assets grew to $209,989 thousand at June 30, 2026, from $169,074 thousand at December 31, 2025, driven in part by higher accounts and other receivables of $97,451 thousand and inventories of $88,081 thousand. Total shareholders' equity was $228,566 thousand at June 30, 2026, up from $216,554 thousand at year-end 2025. Net cash provided by operating activities was $7,677 thousand for the six months ended June 30, 2026, compared with net cash used in operating activities of $2,852 thousand in the comparable 2025 period. Capital expenditures were $9,266 thousand for the first half of 2026.

What Was Disclosed

Tredegar's Form 10-Q for the period ended June 30, 2026 disclosed quarterly and year-to-date income statements, a balance sheet, cash flow statement, and shareholders' equity detail, reflecting higher sales and net income from continuing operations relative to the prior-year periods.